Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (5), R1046-51

Prevalence of Opioid Adverse Events in Chronic Non-Malignant Pain: Systematic Review of Randomised Trials of Oral Opioids

Affiliations
Review

Prevalence of Opioid Adverse Events in Chronic Non-Malignant Pain: Systematic Review of Randomised Trials of Oral Opioids

R Andrew Moore et al. Arthritis Res Ther.

Abstract

Adverse events of opioids may restrict their use in non-cancer pain. Analysis of the incidence of common adverse events in trials conducted in non-cancer pain has usually been limited to opioids used to treat severe pain according to the WHO three-step ladder. To examine the incidence of common adverse events of opioids in non-cancer pain, a systematic review and meta-analysis of information from randomised trials of all opioids in non-cancer pain was undertaken. Studies used were published randomised trials of oral opioid in non-cancer pain, with placebo or active comparator. Thirty-four trials with 5,546 patients were included with 4,212 patients contributing some information on opioid adverse events. Most opioids used (accounting for 90% of patients) were for treating moderate rather than severe pain. Including trials without a placebo increased the amount of information available by 1.4 times. Because of clinical heterogeneity in condition, opioid, opioid dose, duration, and use of titration, only broad results could be calculated. Use of any oral opioid produced higher rates of adverse events than did placebo. Dry mouth (affecting 25% of patients), nausea (21%), and constipation (15%) were the most common adverse events. A substantial proportion of patients on opioids (22%) withdrew because of adverse events. Because most trials were short, less than four weeks, and because few titrated the dose, these results have limited applicability to longer-term use of opioids in clinical practice. Suggestions for improved studies are made.

Figures

Figure 1
Figure 1
Adverse event (AE) rates with opioid and placebo in chronic non-malignant pain.
Figure 2
Figure 2
Adverse event rates in patients with different aetiology of chronic non-malignant pain treated with opioids.

Comment in

Similar articles

See all similar articles

Cited by 97 PubMed Central articles

See all "Cited by" articles

References

    1. World Health Organisation . Cancer Pain Relief. 2. WHO: Geneva; 1996.
    1. Arnér S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11–23. doi: 10.1016/0304-3959(88)90198-4. - DOI - PubMed
    1. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet. 1992;339:1367–1371. doi: 10.1016/0140-6736(92)91194-D. - DOI - PubMed
    1. Large RG, Schug SA. Opioids for chronic pain of non-malignant origin – caring or crippling? Health Care Anal. 1995;3:5–11. - PubMed
    1. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222. doi: 10.1210/jc.85.6.2215. - DOI - PubMed

Substances

LinkOut - more resources

Feedback